- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Juliette Petit: How Nurses Can Prevent Nocebo Effect in Biosimilar Switching
Juliette Petit, MD, a French rheumatologist, talks about her recent study showing that nurses can help curb patient fears and prevent a possible nocebo effect when switching them to a biosimilar.
If you are aware of the placebo effect, you may have heard of its opposite relative, the nocebo effect, where instead of positive thinking leading to an improvement in health, patient fears about drug quality may result in little or no effect from therapy. The nocebo effect is a common concern in the biosimilar space, where patients often doubt whether biosimilars are clinically similar to reference products.
A recent study on the nocebo effect in biosimilar use demonstrated that nurses may be best able to boost patient confidence in biosimilars and improve retention rates. The authors noted that because nurses are usually the first point of contact for patients in the health care system, they can be effective advocates at facilitating switching and biosimilar acceptance.
We sat down with Juliette Petit, MD, a rheumatologist at Saint-Antoine Hospital at Sorbonne University in Paris, France, and one of the study’s co-authors to discuss some of the major points in her study what it could mean for the future of biosimilar uptake.
Learn more about Dr Petit’s study.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
